On January 29, 2020 THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and theranostics, reported that it will publish its 2019 consolidated Full-year annual revenue and its cash position as of December 31, 2019 on Thursday, January 30, 2020 at 5:45 CET (Paris time) (Press release, Theradiag, JAN 29, 2020, View Source [SID1234553639]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On this occasion, Bertrand de Castelnau, Chief Executive Officer, will hold a conference call on Thursday, January 30, 2020, at 6:30 p.m. CET (Paris time) in French only, to answer questions from analysts and investors.

To access the conference call, please dial +33(0)1.70.71.01.59, followed by the code pin 85460157# then follow the instructions.

A replay will be available (in French only) for a period of 90 days by dialing: +33(0)1 72 72 74 02 followed by the access code: 418901569# and then the instructions.

Financial calendar:

2019 Full-year results, March 18, 2020 after market close
Annual General meeting, May 14, 2020
Upcoming events Theradiag will attend:

February 12-15, 2020: 15th ECCO (European Crohn’s and Colitis Organisation) Congress, Vienna, Austria
March 5-6, 2020: Biomed-J 2020 (Young Medical Biologists’ Association), Paris
March 6-7, 2020: GETAID Seminar (Therapeutic Study Group for Inflammatory Digestive Tract Diseases), Paris
March 26-29, 2020: JFHOD congress (Hepato-gastroenterology and Digestive Oncology), Paris.